Cancer centres and hospitals at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

49 cancer centres and hospitals are at ENA 2026 — 103 presentations on the program. Most represented: MD Anderson Cancer Center (10 on the program), Vall d'Hebron Institute of Oncology (VHIO) (8 on the program), Memorial Sloan Kettering Cancer Center (5 on the program). 14 of them have their own page in this guide. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–6 of 49 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Cancer centres & hospitals Cancer treatment and research centre with clinical, laboratory and computational research programmes.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers A super glue to trap wild-type and mutant variants of the ARAF:MEK1 complex Targeted agents Talk Thu Nov 19 8–8:25am Part of Plenary Session 2: RAS pathway: "Targeting RAS - What's Next?" Brief clinical overview, mechanistic insights into resistance and RBD mutation studies Targeted agents Talk Thu Nov 19 4–4:20pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Therapeutic selection – drug design and protein folding AI · Early clinical Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Safety and efficacy of autologous tumor infiltrating lymphocyte therapy in pediatric and adolescent patients with immune checkpoint inhibitor-refractory metastatic melanoma: Results from a phase I clinical trial Targeted agents Talk Fri Nov 20 12:15–12:25pm Part of Plenary Session 6: Proffered papers ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Drug design · Early clinical
Gustave Roussy Villejuif, France
gustaveroussy.fr Cancer centres & hospitals Comprehensive cancer centre combining patient care, research and teaching, with an early-phase drug development department.	Session Thu Nov 19 10–11:30am Plenary Session 3: Proffered Papers Talk Thu Nov 19 3–3:20pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise MTA-cooperative PRMT5 inhibitors in MTAP loss cancers Genomics Session Fri Nov 20 9:30–10:45am Workshop 7: Novel Methodologies & Endpoints in New Drug Development Early clinical Talk Fri Nov 20 10:15–10:30am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development AI Agents in Clinical Trials Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Cancer Genomics Genetic dissection of DNA damage tolerance pathways shaping tobacco-carcinogen-induced mutagenesis Genomics
NEXT Oncology San Antonio, Texas
nextoncology.com Cancer centres & hospitals Network of phase 1 cancer clinical trial sites in the US, Spain and other countries.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates First Results from a First-in-Human Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502, an anti-Nectin-4 ADC, as a Single Agent in Advanced Solid Tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Lineage- and allele-specific coupling of KRAS alterations with NF-kB inflammatory pathway activity in solid tumours Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) Early clinical
Dana-Farber Cancer Institute Boston, MA
dana-farber.org Cancer centres & hospitals Harvard-affiliated cancer treatment and research centre.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Nectin-4 as a therapeutic target in vulvar squamous cell carcinoma and other gynecologic cancers ADCs & radioligands Talk Thu Nov 19 12:30–12:50pm Part of Plenary Session 4: Antibody-Drug Conjugates (ADCs) Antibody drug conjugates: From breakthroughs to clinical practice ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents SF3B1 splicing modulation to overcome platinum and PARP inhibitor resistance in ovarian cancer Targeted agents